RU2007114127A - Полиморфы ингибитора цистеинпротеазы n-(1-цианоциклопропил)-3-циклопропилметансульфонил-2(r)-(2,2,2-трифторо-1(s)-(4-фторфенил) этиламино) пропионамида - Google Patents
Полиморфы ингибитора цистеинпротеазы n-(1-цианоциклопропил)-3-циклопропилметансульфонил-2(r)-(2,2,2-трифторо-1(s)-(4-фторфенил) этиламино) пропионамида Download PDFInfo
- Publication number
- RU2007114127A RU2007114127A RU2007114127/04A RU2007114127A RU2007114127A RU 2007114127 A RU2007114127 A RU 2007114127A RU 2007114127/04 A RU2007114127/04 A RU 2007114127/04A RU 2007114127 A RU2007114127 A RU 2007114127A RU 2007114127 A RU2007114127 A RU 2007114127A
- Authority
- RU
- Russia
- Prior art keywords
- compound
- theta
- approximately
- formula
- pharmaceutical composition
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
- C07D333/02—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings
- C07D333/04—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom
- C07D333/06—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to the ring carbon atoms
- C07D333/14—Radicals substituted by singly bound hetero atoms other than halogen
- C07D333/20—Radicals substituted by singly bound hetero atoms other than halogen by nitrogen atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/04—Drugs for disorders of the respiratory system for throat disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C255/00—Carboxylic acid nitriles
- C07C255/45—Carboxylic acid nitriles having cyano groups bound to carbon atoms of rings other than six-membered aromatic rings
- C07C255/46—Carboxylic acid nitriles having cyano groups bound to carbon atoms of rings other than six-membered aromatic rings to carbon atoms of non-condensed rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C317/00—Sulfones; Sulfoxides
- C07C317/44—Sulfones; Sulfoxides having sulfone or sulfoxide groups and carboxyl groups bound to the same carbon skeleton
- C07C317/48—Sulfones; Sulfoxides having sulfone or sulfoxide groups and carboxyl groups bound to the same carbon skeleton the carbon skeleton being further substituted by singly-bound nitrogen atoms, not being part of nitro or nitroso groups
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C323/00—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups
- C07C323/50—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and carboxyl groups bound to the same carbon skeleton
- C07C323/51—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and carboxyl groups bound to the same carbon skeleton having the sulfur atoms of the thio groups bound to acyclic carbon atoms of the carbon skeleton
- C07C323/60—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and carboxyl groups bound to the same carbon skeleton having the sulfur atoms of the thio groups bound to acyclic carbon atoms of the carbon skeleton with the carbon atom of at least one of the carboxyl groups bound to nitrogen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D211/60—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
- C07D211/62—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals attached in position 4
- C07D211/66—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals attached in position 4 having a hetero atom as the second substituent in position 4
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/24—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
- C07D213/28—Radicals substituted by singly-bound oxygen or sulphur atoms
- C07D213/32—Sulfur atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
- C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
- C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D231/12—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D241/00—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
- C07D241/02—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings
- C07D241/10—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
- C07D241/12—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
- C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
- C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D277/22—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
- C07D277/30—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D309/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings
- C07D309/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
- C07D309/08—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D309/14—Nitrogen atoms not forming part of a nitro radical
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D335/00—Heterocyclic compounds containing six-membered rings having one sulfur atom as the only ring hetero atom
- C07D335/02—Heterocyclic compounds containing six-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C2601/00—Systems containing only non-condensed rings
- C07C2601/02—Systems containing only non-condensed rings with a three-membered ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C2601/00—Systems containing only non-condensed rings
- C07C2601/06—Systems containing only non-condensed rings with a five-membered ring
- C07C2601/08—Systems containing only non-condensed rings with a five-membered ring the ring being saturated
Abstract
1. Соединение Формулы (I),имеющее полиморфную форму, рентгенограмма порошковой дифракции которой имеет характерные пики при приблизительно 6.19, 19.47 и 21.67° (2-тета) (Форма А).2. Соединение Формулы (I):,имеющее полиморфную форму, рентгенограмма порошковой дифракции которой имеет характерные пики при приблизительно 6.19, 8.52, 9.15, 14.42, 17.67, 18.79, 19.47, 19.74, 21.67, 23.16, 23.89, 25.31 и 27.06° (2-тета); ив спектре FT-ИК отмечаются пики при приблизительно 704, 731, 777, 791, 808, 822, 837, 856, 892, 921, 935, 987, 1008, 1028, 1053, 1080, 1115, 1128, 1161, 1180, 1230, 1261, 1288, 1361, 1418, 1465, 1513, 1548, 1607, 1663 и 3349 см(Форма А).3. Соединение Формулы (I):,имеющее полиморфную форму, рентгенограмма порошковой дифракции которой имеет характерный пик при приблизительно 5.65° (2-тета) (Форма В).4. Соединение Формулы (I):,имеющее полиморфную форму, рентгенограмма порошковой дифракции которой имеет характерный пик при приблизительно 5.65, 6.68, 10.12, 18.63, 19.40, 20.66, 21.47, 21.93, 22.47, 23.78, 25.52, 25.76 и 26.79° (2-тета) ив спектре FT-ИК отмечаются пики при приблизительно 704, 731, 791, 808, 823, 837, 856, 893, 936, 1028, 1053, 1080, 1115, 1128, 1161, 1180, 1230, 1287, 1361, 1418, 1465, 1514, 1548, 1607, 1663 и 3349 см(Форма В).5. Соединение Формулы (I):,имеющее полиморфную форму, рентгенограмма порошковой дифракции которой имеет характерные пики при приблизительно 6.24 и 7.50° (2-тета) (Форма С).6. Соединение Формулы (I):,имеющее полиморфную форму, рентгенограмма порошковой дифракции которой имеет широкие пики приблизительно от 5 до 12 и приблизительно от 14 до 25° (2-тета) (Форма D).7. Фармацевтическая композиция, включающая соединение Формулы (I):,имеющее полиморфную форму, рентгенограмма порошковой дифракции которой имеет характерные пики при приблизительно 6.19, 19.47 и 21.67° (2-тета) (Форма А) и фармацевтически приемлемое вспомогательное
Claims (34)
2. Соединение Формулы (I):
имеющее полиморфную форму, рентгенограмма порошковой дифракции которой имеет характерные пики при приблизительно 6.19, 8.52, 9.15, 14.42, 17.67, 18.79, 19.47, 19.74, 21.67, 23.16, 23.89, 25.31 и 27.06° (2-тета); и
в спектре FT-ИК отмечаются пики при приблизительно 704, 731, 777, 791, 808, 822, 837, 856, 892, 921, 935, 987, 1008, 1028, 1053, 1080, 1115, 1128, 1161, 1180, 1230, 1261, 1288, 1361, 1418, 1465, 1513, 1548, 1607, 1663 и 3349 см-1 (Форма А).
4. Соединение Формулы (I):
имеющее полиморфную форму, рентгенограмма порошковой дифракции которой имеет характерный пик при приблизительно 5.65, 6.68, 10.12, 18.63, 19.40, 20.66, 21.47, 21.93, 22.47, 23.78, 25.52, 25.76 и 26.79° (2-тета) и
в спектре FT-ИК отмечаются пики при приблизительно 704, 731, 791, 808, 823, 837, 856, 893, 936, 1028, 1053, 1080, 1115, 1128, 1161, 1180, 1230, 1287, 1361, 1418, 1465, 1514, 1548, 1607, 1663 и 3349 см-1 (Форма В).
8. Фармацевтическая композиция, включающая соединение Формулы (I):
имеющее полиморфную форму, рентгенограмма порошковой дифракции которой имеет характерные пики при приблизительно 6.19, 8.52, 9.15, 14.42, 17.67, 18.79, 19.47, 19.74, 21.67, 23.16, 23.89, 25.31 и 27.06° (2-тета); и
в спектре FT-ИК отмечаются пики при приблизительно 704, 731, 777, 791, 808, 822, 837, 856, 892, 921, 935, 987, 1008, 1028, 1053, 1080, 1115, 1128, 1161, 1180, 1230, 1261, 1288, 1361, 1418, 1465, 1513, 1548, 1607, 1663 и 3349 см-1 (Форма А) и фармацевтически приемлемое вспомогательное вещество.
9. Фармацевтическая композиция, включающая соединение Формулы (I):
которое находится в существенно чистой полиморфной форме, рентгенограмма порошковой дифракции которой имеет характерные пики при приблизительно 6.19, 19.47 и 21.67° (2-тета) (Форма А) и фармацевтически приемлемое вспомогательное вещество.
10. Фармацевтическая композиция по п.9, где Форма А присутствует в количестве, превышающем 95%.
11. Фармацевтическая композиция по п.9, где Форма А присутствует в количестве, превышающем 98%.
13. Фармацевтическая композиция, включающая соединение Формулы (I):
имеющее полиморфную форму, рентгенограмма порошковой дифракции которой имеет характерные пики при приблизительно 5.65, 6.68, 10.12, 18.63, 19.40, 20.66, 21.47, 21.93, 22.47, 23.78, 25.52, 25.76 и 26.79° (2-тета), и
в спектре FT-ИК отмечаются пики при приблизительно 704, 731, 791, 808, 823, 837, 856, 893, 936, 1028, 1053, 1080, 1115, 1128, 1161, 1180, 1230, 1287, 1361, 1418, 1465, 1514, 1548, 1607, 1663 и 3349 см-1 (Форма В), и фармацевтически приемлемое вспомогательное вещество.
15. Фармацевтическая композиция по п.14, где Форма В присутствует в количестве, превышающем 95%.
16. Фармацевтическая композиция по п.14, где Форма В присутствует в количестве, превышающем 98%.
18. Фармацевтическая композиция, включающая соединение Формулы (I):
которое находится в существенно чистой полиморфной форме, рентгенограмма порошковой дифракции которой имеет характерные пики при приблизительно 6.24 и 7.50° (2-тета) (Форма С) и фармацевтически приемлемое вспомогательное вещество.
19. Фармацевтическая композиция по п.18, где Форма С присутствует в количестве, превышающем 95%.
20. Фармацевтическая композиция по п.18, где Форма С присутствует в количестве, превышающем 98%.
22. Фармацевтическая композиция, включающая соединение Формулы (I):
которое находится в существенно чистой полиморфной форме, рентгенограмма порошковой дифракции которой имеет широкие пики приблизительно от 5 до 12 и от 14 до 25° (2-тета) (Форма D) и фармацевтически приемлемое вспомогательное вещество.
23. Фармацевтическая композиция по п.22, где Форма D присутствует в количестве, превышающем 95%.
24. Фармацевтическая композиция по п.22, где Форма D присутствует в количестве, превышающем 98%.
25. Способ лечения заболевания, опосредованного Катепсином S, который включает введение животному фармацевтической композиции по какому-либо из пп.7-24.
26. Способ получения полиморфа соединения N(1-цианоциклопропил)-3-циклопропилметансульфонил-2(R)-[2,2,2-трифтор-1(S)-(4-фторфенил)этиламино]-пропионамида, где указанный способ включает
(a) кристаллизацию соединения из растворителя или смеси растворителей, имеющих достаточное химическое сродство к соединению и не оказывающих существенного влияния на два асимметричных центра соединения в течение процесса кристаллизации и выделение полиморфа в существенно чистой форме; или
(b) кристаллизацию соединения под действием механического напряжения, уменьшения размера частиц соединения, электрического поля или тепловой обработки, не оказывая существенного влияния на целостность соединения или два асимметричных центра соединения в течение процесса кристаллизации и выделение полиморфа в существенно чистой форме; или
(с) сжижение соединения, сопровождаемое быстрым охлаждением сжиженного
соединения, или подвергание соединения уменьшению размера частиц при температурах ниже комнатной температуры, не оказывая существенного влияния на целостность соединения, или два асимметричных центра соединения в течение сжижения или уменьшение размера частиц и выделение полиморфа в существенно чистой аморфной форме.
27. Способ по п.26, включающий комбинацию этапов (а) и (b).
28. Способ по п.26, включающий этап (а).
29. Способ по п.26 или 28, где выделенный полиморф является Формой А соединения.
30. Способ по п.29, где растворитель на этапе (а) является 2-пропанолом.
31. Способ по п.26, где первый полиморф соединения превращается во второй полиморф.
32. Способ по п.31, где первый полиморф и второй полиморф обладают различной термодинамической стабильностью.
33. Способ по п.31, где первый полиморф имеет меньшую термодинамическую стабильность чем второй.
34. Соединение Формулы (I):
имеющее полиморфную форму, которая выбирается из группы, состоящей из
(a) полиморфной формы, рентгенограмма порошковой дифракции которой имеет характерные пики при приблизительно 6.19, 19.47 и 21.67° (2-тета) (Форма А);
(b) полиморфной формы, рентгенограмма порошковой дифракции которой имеет характерный пик при приблизительно 5.65° (2-тета) (Форма В);
(c) полиморфной формы, рентгенограмма порошковой дифракции которой имеет характерные пики при приблизительно 6.24 и 7.50° (2-тета) (Форма С); и
(d) полиморфной формы, рентгенограмма порошковой дифракции которой имеет широкие пики приблизительно от 5 до 12 и приблизительно от 14 до 25° (2-тета) (Форма D).
Applications Claiming Priority (6)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US50468003P | 2003-09-18 | 2003-09-18 | |
US56106204P | 2004-04-09 | 2004-04-09 | |
USPCT/US2004/030442 | 2004-09-17 | ||
US10/943,768 | 2004-09-17 | ||
PCT/US2004/030442 WO2005028429A2 (en) | 2003-09-18 | 2004-09-17 | Haloalkyl containing compounds as cysteine protease inhibitors |
US60/664,244 | 2005-03-21 |
Publications (1)
Publication Number | Publication Date |
---|---|
RU2007114127A true RU2007114127A (ru) | 2008-10-27 |
Family
ID=34381124
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
RU2007114127/04A RU2007114127A (ru) | 2003-09-18 | 2005-09-16 | Полиморфы ингибитора цистеинпротеазы n-(1-цианоциклопропил)-3-циклопропилметансульфонил-2(r)-(2,2,2-трифторо-1(s)-(4-фторфенил) этиламино) пропионамида |
Country Status (19)
Country | Link |
---|---|
US (1) | US7547701B2 (ru) |
EP (1) | EP1663958B1 (ru) |
JP (1) | JP4991295B2 (ru) |
KR (1) | KR20060079143A (ru) |
AU (1) | AU2004274471A1 (ru) |
BR (1) | BRPI0410979A (ru) |
CA (1) | CA2521811A1 (ru) |
DK (1) | DK1663958T3 (ru) |
EA (1) | EA011855B1 (ru) |
ES (1) | ES2534222T3 (ru) |
LV (1) | LV13440B (ru) |
MX (1) | MXPA05012129A (ru) |
NO (1) | NO20061627L (ru) |
NZ (1) | NZ542865A (ru) |
PT (1) | PT1663958E (ru) |
RU (1) | RU2007114127A (ru) |
SG (1) | SG146658A1 (ru) |
TW (1) | TW200524851A (ru) |
WO (1) | WO2005028429A2 (ru) |
Families Citing this family (28)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
BRPI0308208B8 (pt) * | 2002-03-05 | 2021-05-25 | Axys Pharm Inc | compostos inibidores de catepsina cisteína protease e composições farmacêuticas compreendendo os mesmos |
TW200524851A (en) | 2003-09-18 | 2005-08-01 | Axys Pharm Inc | Haloalkyl containing compounds as cysteine protease inhibitors |
JP2007513972A (ja) * | 2003-12-11 | 2007-05-31 | アクシス・ファーマシューティカルズ・インコーポレイテッド | 低分子治療剤または生物製剤の投与によって引き起こされる免疫応答を治療するためのカテプシンsインヒビターの使用 |
WO2005063742A2 (en) * | 2003-12-23 | 2005-07-14 | Axys Pharmaceuticals, Inc. | Amidino compounds as cysteine protease inhibitors |
KR20060129416A (ko) * | 2004-01-30 | 2006-12-15 | 쉐링 악티엔게젤샤프트 | 시스테인 프로테아제 억제제로서의 실리난 화합물 |
CA2580219A1 (en) * | 2004-09-17 | 2006-03-30 | Schering Aktiengesellschaft | Polymorphs of the cysteine protease inhibitor n-(1-cyanocyclopropyl)-3-cyclopropylmethanesulfonyl-2(r)-(2,2,2-trifluoro-1(s)-(4-fluorophenyl) ethylamino)propionamide |
AR055283A1 (es) * | 2004-11-23 | 2007-08-15 | Merck Frosst Canada Ltd | Inhibidores de cisteinproteasa de catepsina |
JP4988589B2 (ja) * | 2004-12-01 | 2012-08-01 | ビロベイ,インコーポレイティド | システインプロテアーゼインヒビターとしてのハロアルキル含有化合物 |
WO2006060810A1 (en) | 2004-12-02 | 2006-06-08 | Schering Aktiengesellschaft | Sulfonamide compounds as cysteine protease inhibitors |
MX2007011617A (es) | 2005-03-21 | 2008-03-13 | Applera Corp | Compuestos de alfa-cetoamida como inhibidores de la cisteina proteasa. |
EP1866277B1 (en) * | 2005-03-22 | 2014-06-25 | Virobay, Inc. | Sulfonyl containing compounds as cysteine protease inhibitors |
JP2008545720A (ja) | 2005-06-02 | 2008-12-18 | メルク フロスト カナダ リミテツド | カテプシン阻害剤としてのフルオロアルキルアミン誘導体 |
GB0611654D0 (en) * | 2006-06-13 | 2006-07-19 | Medivir Ab | Compounds |
WO2008028301A1 (en) * | 2006-09-08 | 2008-03-13 | Merck Frosst Canada Ltd. | Prodrugs of inhibitors of cathepsin s |
US20100048717A1 (en) | 2006-09-25 | 2010-02-25 | MERCK FROSST CANADA LTD, Merk & Co., Inc. | Cathepsin b inhibitors |
KR101555931B1 (ko) | 2006-10-04 | 2015-09-30 | 비로베이, 인코포레이티드 | 시스테인 프로테아제 억제제로서의 디플루오로 함유 화합물 |
US7893112B2 (en) | 2006-10-04 | 2011-02-22 | Virobay, Inc. | Di-fluoro containing compounds as cysteine protease inhibitors |
WO2008070994A1 (en) | 2006-12-14 | 2008-06-19 | Nps Pharmaceuticals, Inc. | Use of d-serine derivatives for the treatment of anxiety disorders |
CN102014635B (zh) * | 2008-04-01 | 2015-12-16 | 维罗贝股份有限公司 | 作为半胱氨酸蛋白酶抑制剂的含二氟化合物 |
JP5198220B2 (ja) * | 2008-11-13 | 2013-05-15 | 東ソ−・エフテック株式会社 | アミノ酸誘導体の製造方法 |
WO2010069069A1 (en) * | 2008-12-17 | 2010-06-24 | Merck Frosst Canada Ltd. | Cathepsin b inhibitors |
EP2445872A4 (en) * | 2009-06-22 | 2012-12-05 | Merck Canada Inc | INHIBITORS OF CATHEPSINE CYSTEINE PROTEASE FOR TREATING VARIED DISEASES |
US8324417B2 (en) * | 2009-08-19 | 2012-12-04 | Virobay, Inc. | Process for the preparation of (S)-2-amino-5-cyclopropyl-4,4-difluoropentanoic acid and alkyl esters and acid salts thereof |
US20130331597A1 (en) * | 2011-03-02 | 2013-12-12 | Guy Humphrey | Amidation process |
WO2012119941A1 (en) | 2011-03-04 | 2012-09-13 | Prozymex A/S | Peptidyl nitrilcompounds as peptidase inhibitors |
MX350121B (es) | 2011-03-18 | 2017-08-28 | Bayer Ip Gmbh | Derivados de n-(3-carbamoilfenil)-1h-pirazol-5-carboxamida y el uso de los mismos para el control de plagas de animales. |
US10494364B2 (en) | 2015-08-29 | 2019-12-03 | Sunshin Lake Pharma Co., Ltd | Cathepsin K inhibitors and application thereof |
EP3946332A1 (en) | 2019-04-05 | 2022-02-09 | Université de Bretagne Occidentale | Protease-activated receptor-2 inhibitors for the treatment of sensory neuropathy induced by a marine neurotoxic poisoning |
Family Cites Families (31)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP3599287B2 (ja) | 1993-04-28 | 2004-12-08 | 三菱化学株式会社 | スルホンアミド誘導体 |
TR200001189T2 (tr) | 1997-11-05 | 2000-09-21 | Novartis Ag. | Dipeptid nitriller. |
CA2360740A1 (en) * | 1999-03-02 | 2000-09-08 | Boehringer Ingelheim Pharmaceuticals, Inc. | Compounds useful as reversible inhibitors of cathepsin s |
DK1178958T3 (da) | 1999-03-15 | 2004-06-21 | Axys Pharm Inc | N-cyanomethylamider som proteaseinhibitorer |
TW200404789A (en) | 1999-03-15 | 2004-04-01 | Axys Pharm Inc | Novel compounds and compositions as protease inhibitors |
US6420364B1 (en) * | 1999-09-13 | 2002-07-16 | Boehringer Ingelheim Pharmaceuticals, Inc. | Compound useful as reversible inhibitors of cysteine proteases |
CA2385130C (en) * | 1999-09-13 | 2009-10-20 | Boehringer Ingelheim Pharmaceuticals, Inc. | Novel spiroheterocyclic compounds useful as reversible inhibitors of cysteine proteases |
WO2001019808A1 (en) * | 1999-09-16 | 2001-03-22 | Axys Pharmaceuticals, Inc. | Chemical compounds and compositions and their use as cathepsin s inhibitors |
ATE387199T1 (de) | 2000-01-06 | 2008-03-15 | Merck Frosst Canada Ltd | Neue substanzen und verbindungen als protease- inhibitoren |
WO2001068645A2 (en) | 2000-03-15 | 2001-09-20 | Axys Pharmaceuticals, Inc. | N-cyanomethylcarboxamides and their use as protease inhibitors |
US7012075B2 (en) | 2001-03-02 | 2006-03-14 | Merck & Co., Inc. | Cathepsin cysteine protease inhibitors |
SE521652C2 (sv) | 2001-03-15 | 2003-11-25 | Canag Diagnostics Ab | En skivepitelcellcancerrelaterad fusionsgen och motsvarande fusionsprotein |
EP1397340A2 (en) | 2001-06-01 | 2004-03-17 | Axys Pharmaceuticals, Inc. | Chemical compounds and pharmaceutical compositions as cathepsin s inhibitors |
JP2005504827A (ja) | 2001-10-02 | 2005-02-17 | ベーリンガー インゲルハイム ファーマシューティカルズ インコーポレイテッド | システインプロテアーゼの可逆性インヒビターとして有用な化合物 |
JP2005508979A (ja) * | 2001-10-29 | 2005-04-07 | ベーリンガー インゲルハイム ファーマシューティカルズ インコーポレイテッド | システインプロテアーゼの可逆性インヒビターとして有用な化合物 |
CA2466115A1 (en) * | 2001-11-13 | 2003-05-22 | Merck Frosst Canada & Co./Merck Frosst Canada & Cie | Cyanoalkylamino derivatives as protease inhibitors |
BRPI0308208B8 (pt) * | 2002-03-05 | 2021-05-25 | Axys Pharm Inc | compostos inibidores de catepsina cisteína protease e composições farmacêuticas compreendendo os mesmos |
JP2006506326A (ja) | 2002-05-14 | 2006-02-23 | アキシーズ ファーマシューティカルズ インク. | システインプロテアーゼ阻害剤 |
WO2004000838A1 (en) * | 2002-06-24 | 2003-12-31 | Axys Pharmaceuticals, Inc. | Peptidic compounds as cysteine protease inhibitors |
EP1551823A1 (en) | 2002-10-08 | 2005-07-13 | Merck Frosst Canada Inc. | 4-amino-azepan-3-one compounds as cathepsin k inhibitors useful in the treatment of osteoporosis |
US7326719B2 (en) | 2003-03-13 | 2008-02-05 | Boehringer Ingelheim Pharmaceuticals, Inc. | Cathepsin S inhibitors |
JP2006526657A (ja) | 2003-06-04 | 2006-11-24 | アクシス ファーマシューティカルズ | システインプロテアーゼ阻害剤としてのアミジノ化合物 |
WO2005021487A1 (en) | 2003-08-27 | 2005-03-10 | Merck Frosst Canada Ltd. | Cathepsin inhibitors |
TW200524851A (en) | 2003-09-18 | 2005-08-01 | Axys Pharm Inc | Haloalkyl containing compounds as cysteine protease inhibitors |
CA2539306A1 (en) | 2003-09-18 | 2005-03-31 | Axys Pharmaceuticals, Inc. | Haloalkyl containing compounds as cysteine protease inhibitors |
PT1667975E (pt) | 2003-09-26 | 2008-02-29 | Glaxo Group Ltd | Forma polimórfica de 3-fenilsulfonil-8-piperazin-1-il-quinolina |
JP2007513972A (ja) | 2003-12-11 | 2007-05-31 | アクシス・ファーマシューティカルズ・インコーポレイテッド | 低分子治療剤または生物製剤の投与によって引き起こされる免疫応答を治療するためのカテプシンsインヒビターの使用 |
WO2005063742A2 (en) | 2003-12-23 | 2005-07-14 | Axys Pharmaceuticals, Inc. | Amidino compounds as cysteine protease inhibitors |
KR20060129416A (ko) | 2004-01-30 | 2006-12-15 | 쉐링 악티엔게젤샤프트 | 시스테인 프로테아제 억제제로서의 실리난 화합물 |
CA2580065A1 (en) | 2004-09-17 | 2006-03-30 | Schering Ag | Processes and intermediates for preparing cysteine protease inhibitors |
AR055283A1 (es) * | 2004-11-23 | 2007-08-15 | Merck Frosst Canada Ltd | Inhibidores de cisteinproteasa de catepsina |
-
2004
- 2004-09-17 TW TW093128291A patent/TW200524851A/zh unknown
- 2004-09-17 JP JP2006527043A patent/JP4991295B2/ja not_active Expired - Fee Related
- 2004-09-17 ES ES04784332.1T patent/ES2534222T3/es active Active
- 2004-09-17 KR KR1020057022300A patent/KR20060079143A/ko not_active Application Discontinuation
- 2004-09-17 SG SG200806916-3A patent/SG146658A1/en unknown
- 2004-09-17 EP EP04784332.1A patent/EP1663958B1/en active Active
- 2004-09-17 NZ NZ542865A patent/NZ542865A/en unknown
- 2004-09-17 EA EA200600588A patent/EA011855B1/ru not_active IP Right Cessation
- 2004-09-17 BR BRPI0410979-1A patent/BRPI0410979A/pt not_active IP Right Cessation
- 2004-09-17 US US10/943,768 patent/US7547701B2/en active Active
- 2004-09-17 WO PCT/US2004/030442 patent/WO2005028429A2/en active Application Filing
- 2004-09-17 PT PT47843321T patent/PT1663958E/pt unknown
- 2004-09-17 DK DK04784332.1T patent/DK1663958T3/da active
- 2004-09-17 CA CA002521811A patent/CA2521811A1/en not_active Abandoned
- 2004-09-17 AU AU2004274471A patent/AU2004274471A1/en not_active Abandoned
- 2004-09-17 MX MXPA05012129A patent/MXPA05012129A/es unknown
-
2005
- 2005-09-16 RU RU2007114127/04A patent/RU2007114127A/ru not_active Application Discontinuation
-
2006
- 2006-03-23 LV LVP-06-49A patent/LV13440B/lv unknown
- 2006-04-10 NO NO20061627A patent/NO20061627L/no not_active Application Discontinuation
Also Published As
Publication number | Publication date |
---|---|
WO2005028429A2 (en) | 2005-03-31 |
US7547701B2 (en) | 2009-06-16 |
PT1663958E (pt) | 2015-06-01 |
AU2004274471A1 (en) | 2005-03-31 |
TW200524851A (en) | 2005-08-01 |
WO2005028429A3 (en) | 2005-05-19 |
ES2534222T3 (es) | 2015-04-20 |
US20050182096A1 (en) | 2005-08-18 |
EP1663958B1 (en) | 2015-02-25 |
EA011855B1 (ru) | 2009-06-30 |
KR20060079143A (ko) | 2006-07-05 |
CA2521811A1 (en) | 2005-03-31 |
SG146658A1 (en) | 2008-10-30 |
DK1663958T3 (da) | 2015-04-07 |
EA200600588A1 (ru) | 2006-08-25 |
MXPA05012129A (es) | 2006-02-08 |
NZ542865A (en) | 2009-04-30 |
NO20061627L (no) | 2006-04-10 |
JP4991295B2 (ja) | 2012-08-01 |
JP2007505920A (ja) | 2007-03-15 |
BRPI0410979A (pt) | 2006-07-04 |
LV13440B (en) | 2006-10-20 |
EP1663958A2 (en) | 2006-06-07 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
RU2007114127A (ru) | Полиморфы ингибитора цистеинпротеазы n-(1-цианоциклопропил)-3-циклопропилметансульфонил-2(r)-(2,2,2-трифторо-1(s)-(4-фторфенил) этиламино) пропионамида | |
JP2005522503A5 (ru) | ||
KR101207529B1 (ko) | 4-치환된 피롤리딘-2-온 및 이들의 용도 | |
WO2014157612A1 (ja) | (1s,4s,5s)-4-ブロモ-6-オキサビシクロ[3.2.1]オクタン-7-オンの製造方法 | |
CA2495685A1 (en) | Aza-bicycloalkyl ethers and their use as alpha7-nachr agonists | |
CN1227233C (zh) | 纯晶形的5-氯-3-(4-甲磺酰基苯基)-6′-甲基-[2,3′]联吡啶及其合成方法 | |
JPH0358967A (ja) | 〔R―(R‖,R‖)〕―2―(4―フルオロフエニル)―β,δ―ジヒドロキシ―5―(1―メチルエチル)―3―フエニル―4―〔(フエニルアミノ)カルボニル〕―1H―ピロール―1―ヘプタン酸、そのラクトン体およびその塩 | |
JP2005509025A5 (ru) | ||
WO2007013086A1 (en) | Novel polymorphs of tenofovir disoproxil fumarate | |
CA2426393C (en) | Crystalline forms of venlafaxine hydrochloride | |
RU2006142768A (ru) | Способ получения бисульфата атазанавира | |
CN111954663A (zh) | 氟化的4-(取代的氨基)苯基氨基甲酸酯衍生物 | |
RU2004120285A (ru) | Новый кристаллический полиморф гидрохлорида венлафаксина и способы его получения | |
Ashwood et al. | Synthesis and antihypertensive activity of pyran oxygen and amide nitrogen replacement analogs of the potassium channel activator cromakalim | |
JP2022553148A (ja) | アバプリチニブの多形及び多形を調製するための方法 | |
WO2002012244A2 (en) | Polymorphs of zaleplon and methods for the preparation thereof | |
AU2001283119A1 (en) | Polymorphs of zaleplon and methods for the preparation thereof | |
FR2483929A1 (fr) | Nouvelles adenosines n6-substituees utiles comme medicaments antihypertenseurs, compositions therapeutiques et formes pharmaceutiques les contenant, et leur procede de preparation | |
JP2002516302A5 (ru) | ||
CA2598579A1 (en) | Crystalline forms of (1rs,3rs,6rs)-6-dimethvlaminomethvl-1-(3-methoxv- phenyl)cyclohexane-1 ,3-diol hydrochloride | |
CHIBA et al. | Total syntheses of spidamine and joramine, polyamine toxins from the joro spider, Nephila clavata | |
MXPA06002145A (es) | Compuestos de cicloalquilaminoacidos, procedimiento para su elaboracion y sus usos. | |
SU857139A1 (ru) | Способ получени порфиринов,содержащих изоциклическое метилциклопентановое кольцо | |
JP2009502755A (ja) | 筋弛緩作用及び消炎作用を有するチオコルヒコシド類縁体 | |
CN1347404A (zh) | (-)-马鞭烯酮衍生物 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FA93 | Acknowledgement of application withdrawn (no request for examination) |
Effective date: 20081126 |